Cellectis S.A. (CLLS) is a Biotechnology company in the Healthcare sector, currently trading at $4.09. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CLLS = $6 (+46.7% upside).
Valuation: CLLS trades at a trailing Price-to-Earnings (P/E) of -5.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.23.
Financials: revenue is $73M, +1792.6%/yr average growth. Net income is $68M (loss), growing at -7.7%/yr. Net profit margin is -92.7% (negative). Gross margin is 72.5% (-18.3 pp trend).
Balance sheet: total debt is $120M against $76M equity (Debt-to-Equity (D/E) ratio 1.58, leveraged). Current ratio is 1.62 (strong liquidity). Debt-to-assets is 36.9%. Total assets: $325M.
Analyst outlook: 13 / 16 analysts rate CLLS as buy (81%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 97/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 35/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).
